News >

Pembrolizumab Shows Promise for Unmet Need in NMIBC

Brandon Scalea
Published: Wednesday, May 22, 2019

Arjun V. Balar, MD
Arjun V. Balar, MD
Early data indicate that pembrolizumab (Keytruda) is a feasible option for patients with high-risk nonmuscle–invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guérin (BCG), explained Arjun V. Balar, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x